Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-21-004751
Filing Date
2021-03-15
Accepted
2021-03-15 17:01:47
Documents
5
Period of Report
2021-04-27

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2021proxystatement.htm DEF 14A 502933
2 GRAPHIC cumberlandlogoa02a011.jpg GRAPHIC 12534
3 GRAPHIC cumberlandpharmalogoa011.jpg GRAPHIC 37721
4 GRAPHIC image41.jpg GRAPHIC 10605
5 GRAPHIC xa011.jpg GRAPHIC 2405
  Complete submission text file 0001628280-21-004751.txt   591648
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33637 | Film No.: 21742244
SIC: 2834 Pharmaceutical Preparations